Advanced search
Publication Cover
Blood Pressure Volume 30, 2021 - Issue 1
Submit an article Journal homepage
2,804
Views
16
CrossRef citations to date
0
Altmetric
Editorial

Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers

Sverre E. Kjeldsena Departments of Cardiology and Nephrology, University of Oslo, Ullevaal Hospital, Oslo, Norway;b Department of Nephrology, University of Oslo, Ullevaal Hospital, Oslo, NorwayCorrespondence[email protected]
,
Krzysztof Narkiewiczc Department of Hypertension and Diabetology, Medical University of Gdansk, Gdańsk, Poland
,
Michel Burnierd Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
&
Suzanne Oparile Vascular Biology and Hypertension Program, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
Pages 1-3 | Published online: 21 Dec 2020

References

  • Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781–782.
  • Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41:1801–1803.
  • Sharma RK, Stevens BR, Obukhov AG, et al. ACE2 (angiotensin-converting enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2. Hypertension. 2020;76:651–661.
  • Kreutz R, El-Hady EA, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116:1688–1699.
  • Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382–1385.
  • Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–2440.
  • Lopes RD, Macedo AVS, de Barros E Silva PGM, et al.; BRACE CORONA investigators. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-The BRACE CORONA Trial. Am Heart J. 2020;226:49–59.
  • Mancia G. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial. Cardiovasc Res. 2020;116:e198–e199.
  • Savarese G, Benson L, Sundström J, et al. Association between renin-angiotensin-aldosterone system inhibitor use and covid-19 hospitalization and death: a 1.4 million patient nation-wide registry analysis. Eur J Heart Failure. 2020; in press. DOI: 10.1002/ejhf.2060
  • Pinto-Sietsma S-J, Flossdorf M, Buchholtz VR, et al. Antihypertensive drugs in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6:415–416.
  • Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382:2441–2448.
  • Barbieri A, Robinson N, Palma G, et al. Can beta-2-adrenergic pathway be a new target to combat SARS-COV-2 hyperinflammatory syndrome? Lessons learned from cancer. Front Immunol. 2020;11:588724.
  • Yan F, Huang F, Xu J, et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly Covid-19 patients. Cell Discov. 2020;6:77.
  • Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand. 2003;177:385–390.
  • Kubon C, Mistry NB, Grundvold I, et al. The role of beta-blockers in the treatment of chronic heart failure. Trends Pharmacol Sci. 2011;32:206–212.
  • Vasanthakumar N. Beta-adrenergic blockers as a potential treatment for Covid-19 patients. BioEssays. 2020;42:2000094.
  • Heriansya T, Chomsy IN, Febrianda R, et al. The potential benefit of beta-blockers for the management of Covid-19 protocol therapy-induced QT prolongation: a literature review. Sci. Pharm. 2020; 88:0055.
  • Ayoub N. Carvedilol as a potential addition to the Covid-19 therapeutic arsenal. Int J Pharmacy Pharm Sci. 2020;12:87–89.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.